The FDA has approved aceclidine eye drops for the treatment of presbyopia, a condition associated with age-related farsightedness. Aceclidine constricts the pupillary sphincter, which helps the eye focus on objects directly in front of the eye. The medication is administered once daily; its effects begin within half an hour and last for up to ten hours.
The drug was approved based on three clinical trials involving 1,060 participants. Participants tolerated the drug well, and rare side effects included eye irritation, blurred vision, and headache, which were mostly short-lived and resolved on their own. The drug will be available to patients at the end of 2025.
